Mediar Therapeutics

Mediar Therapeutics is a preclinical stage biotech company with a mission to develop innovative treatments to halt or even reverse fibrosis. The company takes a pioneering approach by targeting the fibrotic mediators driving disease progression. Founded in 2019, Mediar is deeply rooted in its understanding of the complex science underlying fibrosis. By combining novel targets with reliable blood biomarkers and familiar modalities, the company minimizes risk in the development of fibrosis therapies, thus presenting a promising future for clinical development. The startup recently secured an $85.00M Series A investment on 15 March 2023, signaling strong confidence from a cohort of prominent investors including Novartis Venture Fund, Sofinnova Partners, GIMV, BB Pureos Bioventures, Mission BioCapital, ShangPharma, Mass General Brigham Ventures, Pfizer Venture Investments, Eli Lilly & Company Foundation, and Bristol-Myers Squibb. This substantial investment not only provides the necessary capital for further research and development but also validates Mediar Therapeutics' potential within the biotechnology and healthcare industries. Overall, Mediar Therapeutics presents an intriguing investment opportunity in the biotech sector, with its innovative approach to addressing fibrosis and the substantial support it has garnered from leading investors. For more information, interested parties can contact [email protected].